交易 Recursion Pharmaceuticals, Inc. - RXRX CFD
加入收藏夹- 概括
- 历史数据
- 活动
- 收入报表
- 资产负债表
- 现金流
- 所有权
交易条件
价差 | 0.07 | ||||||||
多头隔夜费
Long position overnight fee
前往平台 | -0.030779% | ||||||||
空头隔夜费
Short position overnight fee
前往平台 | -0.013666% | ||||||||
隔夜费时间 | 22:00 (UTC) | ||||||||
最小交易量 | 1 | ||||||||
货币 | USD | ||||||||
保证金 | 20% | ||||||||
上市交易所 | United States of America | ||||||||
交易费 | 0% |
*Information provided by Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | 平倉 | Change | Change (%) | 開倉 | High | Low |
---|---|---|---|---|---|---|
Feb 3, 2023 | 9.63 | 0.45 | 4.90% | 9.18 | 9.70 | 8.99 |
Feb 2, 2023 | 9.34 | 0.79 | 9.24% | 8.55 | 9.60 | 8.54 |
Feb 1, 2023 | 8.53 | 0.28 | 3.39% | 8.25 | 8.67 | 7.93 |
Jan 31, 2023 | 8.29 | 0.19 | 2.35% | 8.10 | 8.43 | 8.10 |
Jan 30, 2023 | 8.04 | -0.15 | -1.83% | 8.19 | 8.48 | 7.95 |
Jan 27, 2023 | 8.49 | 0.41 | 5.07% | 8.08 | 8.65 | 8.08 |
Jan 26, 2023 | 8.17 | -0.08 | -0.97% | 8.25 | 8.28 | 7.91 |
Jan 25, 2023 | 8.18 | -0.14 | -1.68% | 8.32 | 8.32 | 7.71 |
Jan 24, 2023 | 8.56 | 0.15 | 1.78% | 8.41 | 8.84 | 8.32 |
Jan 23, 2023 | 8.67 | 0.13 | 1.52% | 8.54 | 8.92 | 8.24 |
Jan 20, 2023 | 8.61 | -0.01 | -0.12% | 8.62 | 8.68 | 8.33 |
Jan 19, 2023 | 8.43 | -0.19 | -2.20% | 8.62 | 8.84 | 8.22 |
Jan 18, 2023 | 8.90 | -0.32 | -3.47% | 9.22 | 9.45 | 8.90 |
Jan 17, 2023 | 9.15 | 0.15 | 1.67% | 9.00 | 9.44 | 8.85 |
Jan 13, 2023 | 8.64 | 0.18 | 2.13% | 8.46 | 8.97 | 8.37 |
Jan 12, 2023 | 8.67 | 0.85 | 10.87% | 7.82 | 8.68 | 7.68 |
Jan 11, 2023 | 7.89 | 0.21 | 2.73% | 7.68 | 7.96 | 7.60 |
Jan 10, 2023 | 7.75 | 0.36 | 4.87% | 7.39 | 7.81 | 7.38 |
Jan 9, 2023 | 7.49 | 0.01 | 0.13% | 7.48 | 7.85 | 7.36 |
Jan 6, 2023 | 7.40 | 0.07 | 0.95% | 7.33 | 7.51 | 7.03 |
Recursion Pharmaceuticals, Inc. Events
Time (UTC) | Country | Event |
---|---|---|
No events scheduled |
- 年度
- 每季度
2019 | 2020 | 2021 | |
---|---|---|---|
总收入 | 2.319 | 3.962 | 10.178 |
收入 | 2.319 | 3.962 | 10.178 |
总营业费用 | 65.315 | 89.46 | 193.78 |
销售/一般/行政费用,总计 | 19.898 | 27.035 | 66.671 |
研究与开发 | 44.862 | 61.542 | 125.978 |
异常费用(收入) | 0.555 | 0.883 | 0.827 |
营业收入 | -62.996 | -85.498 | -183.602 |
利息收入(费用),非经营净值 | 1.106 | -1.024 | -2.879 |
其他,净值 | 0.011 | -0.484 | 0.002 |
税前净收入 | -61.879 | -87.006 | -186.479 |
税后净收入 | -61.879 | -87.006 | -186.479 |
未计算非常项目前的净收益 | -61.879 | -87.006 | -186.479 |
净收入 | -61.879 | -87.006 | -186.479 |
普通股股东可获收益 (不含非经常性项目) | -61.879 | -87.006 | -186.479 |
普通股股东可获收益 (含非經常性項目) | -61.879 | -87.006 | -186.479 |
摊薄净收入 | -61.879 | -87.006 | -186.479 |
摊薄后加权平均股 | 162.155 | 162.155 | 125.348 |
扣除特别项目的每股摊薄盈利 | -0.3816 | -0.53656 | -1.48769 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | |
每股正常摊薄盈利 | -0.37818 | -0.53111 | -1.48109 |
Depreciation / Amortization | 0.304 |
Q1 2021 | Q2 2021 | Q3 2021 | Q4 2021 | Q1 2022 | |
---|---|---|---|---|---|
总收入 | 2.562 | 2.549 | 2.534 | 2.533 | 5.333 |
收入 | 2.562 | 2.549 | 2.534 | 2.533 | 5.333 |
总营业费用 | 33.046 | 43.478 | 49.763 | 67.493 | 61.314 |
销售/一般/行政费用,总计 | 8.937 | 13.854 | 15.69 | 21.419 | 21.074 |
研究与开发 | 24.033 | 29.548 | 33.17 | 45.998 | 32.365 |
Depreciation / Amortization | 0.076 | 0.076 | 0.076 | 0.076 | 0.076 |
营业收入 | -30.484 | -40.929 | -47.229 | -64.96 | -55.981 |
利息收入(费用),非经营净值 | -0.233 | -2.472 | -0.17 | -0.002 | 0.073 |
税前净收入 | -30.717 | -43.401 | -47.428 | -64.933 | -55.979 |
税后净收入 | -30.717 | -43.401 | -47.428 | -64.933 | -55.979 |
未计算非常项目前的净收益 | -30.717 | -43.401 | -47.428 | -64.933 | -55.979 |
净收入 | -30.717 | -43.401 | -47.428 | -64.933 | -55.979 |
普通股股东可获收益 (不含非经常性项目) | -30.717 | -43.401 | -47.428 | -64.933 | -55.979 |
普通股股东可获收益 (含非經常性項目) | -30.717 | -43.401 | -47.428 | -64.933 | -55.979 |
摊薄净收入 | -30.717 | -43.401 | -47.428 | -64.933 | -55.979 |
摊薄后加权平均股 | 168.321 | 138.361 | 168.534 | 169.853 | 170.69 |
扣除特别项目的每股摊薄盈利 | -0.18249 | -0.31368 | -0.28142 | -0.38229 | -0.32796 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
每股正常摊薄盈利 | -0.18249 | -0.31368 | -0.27651 | -0.38229 | -0.32796 |
异常费用(收入) | 0.827 | 0 | |||
其他,净值 | -0.029 | 0.029 | -0.071 | ||
收入成本,共计 | 7.799 | ||||
毛利 | -2.466 |
- 年度
- 每季度
2019 | 2020 | 2021 | |
---|---|---|---|
流动资产总额 | 76.398 | 266.437 | 534.718 |
现金和短期投资 | 69.883 | 262.126 | 516.562 |
现金等价物 | 69.883 | 262.126 | 285.116 |
应收账款总额,净额 | 0.151 | 0.156 | 9.09 |
Accounts Receivable - Trade, Net | 0.151 | 0.156 | 0.034 |
Other Current Assets, Total | 6.364 | 4.155 | 9.066 |
Total Assets | 101.431 | 298.585 | 610.345 |
Property/Plant/Equipment, Total - Net | 24.37 | 25.967 | 64.725 |
Property/Plant/Equipment, Total - Gross | 30.085 | 35.929 | 83.462 |
Accumulated Depreciation, Total | -5.715 | -9.962 | -18.737 |
Intangibles, Net | 0 | 1.689 | 1.385 |
Other Long Term Assets, Total | 0.663 | 3.691 | 8.716 |
Total Current Liabilities | 6.684 | 23.099 | 46.658 |
Accounts Payable | 1.261 | 1.074 | 2.819 |
Accrued Expenses | 5.346 | 10.952 | 33.749 |
Notes Payable/Short Term Debt | 0 | 0 | 0 |
Current Port. of LT Debt/Capital Leases | 0.077 | 1.073 | 0.09 |
Other Current Liabilities, Total | 0 | 10 | 10 |
Total Liabilities | 24.587 | 56.562 | 67.407 |
Total Long Term Debt | 12.418 | 11.414 | 0.633 |
Long Term Debt | 12.418 | 11.414 | 0.633 |
Other Liabilities, Total | 5.485 | 22.049 | 20.116 |
Total Equity | 76.844 | 242.023 | 542.938 |
Preferred Stock - Non Redeemable, Net | 201.109 | 448.312 | 0 |
Common Stock | 0 | 0 | 0.002 |
Additional Paid-In Capital | 2.33 | 7.312 | 943.142 |
Retained Earnings (Accumulated Deficit) | -126.595 | -213.601 | -400.08 |
Total Liabilities & Shareholders’ Equity | 101.431 | 298.585 | 610.345 |
Total Common Shares Outstanding | 162.155 | 162.155 | 170.272 |
短期投资 | 0 | 231.446 | |
Goodwill, Net | 0.801 | 0.801 | |
Other Equity, Total | 0 | -0.126 |
Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | |
---|---|---|---|---|---|
流动资产总额 | 221.822 | 647.635 | 600.87 | 534.718 | 619.455 |
现金和短期投资 | 214.088 | 632.738 | 578.91 | 516.562 | 591.105 |
现金等价物 | 214.088 | 632.738 | 394.721 | 285.116 | 507.891 |
应收账款总额,净额 | 0.071 | 0.049 | 2.282 | 9.09 | 11.397 |
Accounts Receivable - Trade, Net | 0.071 | 0.049 | 0.034 | 0.034 | 0.034 |
Other Current Assets, Total | 7.663 | 14.848 | 19.678 | 9.066 | 16.953 |
Total Assets | 271.943 | 698.59 | 658.606 | 610.345 | 734.319 |
Property/Plant/Equipment, Total - Net | 44.642 | 48.549 | 55.439 | 64.725 | 104.005 |
Property/Plant/Equipment, Total - Gross | 56.036 | 62.306 | 71.662 | 83.462 | 125.433 |
Accumulated Depreciation, Total | -11.394 | -13.757 | -16.223 | -18.737 | -21.428 |
Intangibles, Net | 2.414 | 2.338 | 2.262 | 1.385 | 1.309 |
Other Long Term Assets, Total | 3.065 | 0.068 | 0.035 | 8.716 | 8.749 |
Total Current Liabilities | 26.854 | 29.54 | 42.943 | 46.658 | 85.705 |
Accounts Payable | 3.125 | 3.196 | 6.326 | 2.819 | 4.162 |
Accrued Expenses | 11.584 | 13.209 | 26.529 | 33.749 | 27.204 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Port. of LT Debt/Capital Leases | 2.145 | 3.135 | 0.088 | 0.09 | 0.092 |
Other Current Liabilities, Total | 10 | 10 | 10 | 10 | 54.247 |
Total Liabilities | 56.662 | 55.876 | 59.574 | 67.407 | 240.753 |
Total Long Term Debt | 10.339 | 9.423 | 0.656 | 0.633 | 0.61 |
Long Term Debt | 10.339 | 9.423 | 0.656 | 0.633 | 0.61 |
Other Liabilities, Total | 19.469 | 16.913 | 15.975 | 20.116 | 154.438 |
Total Equity | 215.281 | 642.714 | 599.032 | 542.938 | 493.566 |
Redeemable Preferred Stock | 450.85 | ||||
Preferred Stock - Non Redeemable, Net | -2.538 | 0 | 0 | 0 | |
Common Stock | 0 | 0.002 | 0.002 | 0.002 | 0.002 |
Additional Paid-In Capital | 11.287 | 930.431 | 934.175 | 943.142 | 949.932 |
Retained Earnings (Accumulated Deficit) | -244.318 | -287.719 | -335.147 | -400.08 | -456.059 |
Total Liabilities & Shareholders’ Equity | 271.943 | 698.59 | 658.606 | 610.345 | 734.319 |
Total Common Shares Outstanding | 168.321 | 168.426 | 168.635 | 170.272 | 171.078 |
短期投资 | 184.189 | 231.446 | 83.214 | ||
Other Equity, Total | 0.002 | -0.126 | -0.309 | ||
Goodwill, Net | 0.801 | 0.801 |
- 年度
- 每季度
2019 | 2020 | 2021 | |
---|---|---|---|
净收入/起跑线 | -61.879 | -87.006 | -186.479 |
经营活动产生的现金 | -57.042 | -45.399 | -158.614 |
经营活动产生的现金 | 3.543 | 4.442 | 8.405 |
非现金物品 | 0.886 | 6.331 | 19.766 |
已付现金利息 | 0.485 | 0.989 | 0.68 |
营运资金的变化 | 0.408 | 30.834 | -0.306 |
投资活动产生的现金 | -3.91 | -8.74 | -271.744 |
资本支出 | -3.91 | -5.831 | -39.798 |
其他投资现金流量项目,总计 | 0 | -2.909 | -231.946 |
融资活动产生的现金 | 120.41 | 246.135 | 458.54 |
融资现金流项目 | -0.275 | 0 | 0 |
股票的发行(报废),净额 | 119.98 | 239.812 | 471.338 |
债务的发行(退还),净额 | 0.705 | 6.323 | -12.798 |
现金净变化 | 59.458 | 191.996 | 28.182 |
Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | |
---|---|---|---|---|---|
Net income/Starting Line | -30.717 | -74.118 | -121.546 | -186.479 | -55.979 |
Cash From Operating Activities | -30.755 | -64.408 | -97.456 | -158.614 | 77.388 |
Cash From Operating Activities | 1.402 | 3.733 | 6.169 | 8.405 | 2.767 |
Non-Cash Items | 1.922 | 9.614 | 14.268 | 19.766 | 7.776 |
Cash Interest Paid | 0.254 | 0.54 | 0.665 | 0.68 | 0.014 |
Changes in Working Capital | -3.362 | -3.637 | 3.653 | -0.306 | 122.824 |
Cash From Investing Activities | -19.416 | -25.628 | -219.501 | -271.744 | 143.304 |
Capital Expenditures | -19.416 | -25.628 | -35.334 | -39.798 | -4.342 |
Cash From Financing Activities | 2.134 | 465.839 | 454.744 | 458.54 | 2.084 |
Issuance (Retirement) of Stock, Net | 2.154 | 465.879 | 462.901 | 471.338 | 2.106 |
Issuance (Retirement) of Debt, Net | -0.02 | -0.04 | -12.777 | -12.798 | -0.022 |
Net Change in Cash | -48.037 | 375.803 | 137.787 | 28.182 | 222.776 |
Other Investing Cash Flow Items, Total | 0 | -184.167 | -231.946 | 147.646 | |
Financing Cash Flow Items | 4.62 |
投资者名称 | 投资者类型 | 流通股百分比 | 持有股份 | 股份变动 | 持有日期 | 换手率 |
---|---|---|---|---|---|---|
Baillie Gifford & Co. | Investment Advisor | 13.6608 | 24820850 | 3226157 | 2022-12-31 | LOW |
Mubadala Investment Company PJSC | Sovereign Wealth Fund | 11.4375 | 20781376 | 535976 | 2023-01-26 | LOW |
Lux Capital Management, LLC | Venture Capital | 7.1667 | 13021519 | 0 | 2022-03-31 | LOW |
DCVC Management Co, LLC | Venture Capital | 5.4444 | 9892261 | 0 | 2022-09-30 | LOW |
MIC Capital Management UK LLP | Investment Advisor | 4.6516 | 8451758 | 0 | 2022-09-30 | HIGH |
The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 4.6084 | 8373178 | 1393519 | 2022-09-30 | LOW |
BlackRock Institutional Trust Company, N.A. | Investment Advisor | 4.5728 | 8308494 | 1476128 | 2022-09-30 | LOW |
Kinnevik AB | Venture Capital | 4.212 | 7653061 | 7653061 | 2022-12-31 | LOW |
Borgeson (Blake Charles) | Individual Investor | 4.1894 | 7611827 | -16445 | 2023-01-24 | LOW |
Laurion Capital Management LP | Hedge Fund | 2.5247 | 4587274 | 0 | 2022-09-30 | HIGH |
State Street Global Advisors (US) | Investment Advisor/Hedge Fund | 2.5074 | 4555759 | 2430027 | 2022-09-30 | LOW |
Fidelity Management & Research Company LLC | Investment Advisor | 2.3397 | 4251164 | 1415312 | 2022-09-30 | LOW |
Obvious Ventures | Venture Capital | 2.1933 | 3985087 | -1992544 | 2022-09-30 | LOW |
Li (Dean Y) | Individual Investor | 2.0937 | 3804102 | 1573 | 2023-01-03 | LOW |
AllianceBernstein L.P. | Investment Advisor/Hedge Fund | 1.7818 | 3237344 | -363616 | 2022-09-30 | LOW |
ARK Investment Management LLC | Investment Advisor | 1.7059 | 3099490 | -260321 | 2022-12-31 | LOW |
Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 1.2835 | 2332083 | 826087 | 2022-09-30 | LOW |
Platinum Asset Management | Investment Advisor/Hedge Fund | 1.2394 | 2251971 | -283651 | 2022-09-30 | LOW |
Menlo Ventures | Venture Capital | 1.0853 | 1971908 | 0 | 2022-12-31 | MED |
Credit Suisse Asset Management | Investment Advisor/Hedge Fund | 0.861 | 1564459 | -340 | 2022-09-30 | LOW |
为什么选择 Capital.com?让我们的数字来说话。
Capital.com Group交易計算器
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
貿易佣金
0
- 1:1
- 2:1
- 5:1
- 10:1
- 20:1
杠杆
20:1
- 20
- 100
- 500
- 1000
- 10000
投資
交易規模(槓桿 x 投資):
開倉
平倉
做空 做多
Recursion Pharmaceuticals, Inc. Company profile
关于 Recursion Pharmaceuticals Inc.
Recursion Pharmaceuticals, Inc.是一家处于临床阶段的生物技术公司。 公司使用Recursion操作系统(Recursion OS),这是一个多层系统,用于生成、分析并从生物和化学数据集中获得洞察力。 它由三部分组成。 基础设施层、Recursion数据宇宙和Recursion地图。 其项目包括REC-4881、REC-3599、REC-2282、REC-994、治疗艰难梭菌结肠炎的先导分子、治疗神经炎症的先导分子、治疗巴顿病的先导分子和治疗CMT2A的先导分子。
Industry: | Bio Therapeutic Drugs |
41S Rio Grande Street
SALT LAKE CITY
UTAH 84101
US
收入报表
- Annual
- Quarterly
人们也观看
还在找一位您可以信任的经纪商吗?
加入成为全球485,000万多名交易者的一份子,选择利用Capital.com进行交易吧。